Products & Services · Total revenues
Repatha — Total revenues
Amgen Repatha — Total revenues increased by 1043.0% to $8.62B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.8%, from $8.15B to $8.62B. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates successful market penetration, expanded insurance coverage, or increased physician adoption, while a decrease may signal heightened competition from biosimilars or alternative therapies.
Detailed definition
This metric represents the total gross revenue generated from the global sales of a specific biologic therapeutic produc...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or therapeutic product lines at other large-cap pharmaceutical and biotechnology companies.
Metric ID:
amgn_segment_repatha_total_revenuesHistorical Data
32 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $6.71B | $6.85B | $6.24B | $6.59B | $6.65B | $6.84B | $6.11B | $408.75M | $6.99B | $408.75M | $6.9B | $408.75M | $8.2B | $408.75M | $7.45B | $555.5M | $8.39B | $555.5M | $8.5B | $555.5M | $9.09B | $555.5M | $8.15B | $754M | $9.18B | $754M | $9.56B | $754M | $9.87B | $754M | $8.62B |
| QoQ Change | — | +2.8% | +2.1% | -8.9% | +5.7% | +0.9% | +2.8% | -10.7% | -93.3% | >999% | -94.1% | >999% | -94.1% | >999% | -95.0% | >999% | -92.5% | >999% | -93.4% | >999% | -93.5% | >999% | -93.9% | >999% | -90.7% | >999% | -91.8% | >999% | -92.1% | >999% | -92.4% | >999% |
| YoY Change | — | — | — | — | +1.0% | -0.8% | -0.1% | -2.1% | -93.4% | +5.9% | -93.8% | +3.8% | -93.9% | +19.8% | -94.0% | +22.0% | -90.9% | +20.1% | -92.0% | +23.2% | -92.0% | +10.9% | -93.2% | +9.4% | -89.9% | +9.4% | -91.0% | +12.4% | -91.1% | +8.6% | -91.7% | +5.8% |
Range$408.75M – $9.87B
CAGR+3.7%
Avg YoY Growth-34.2%
Median YoY Growth-0.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's repatha — total revenues?
- Amgen (AMGN) reported repatha — total revenues of $8.62B in Q1 2026.
- How has Amgen's repatha — total revenues changed year-over-year?
- Amgen's repatha — total revenues increased by 5.8% year-over-year, from $8.15B to $8.62B.
- What does repatha — total revenues mean?
- The total sales revenue generated by the company's specific cholesterol-lowering drug product line.